ArticleBreast cancer (Tokyo, Japan)2026
Adjuvant radiotherapy and survival in patients with malignant phyllode tumors: a population-based retrospective study.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess whether adjuvant radiotherapy (RT) confers a survival benefit in patients with malignant phyllodes tumors of the breast (MPTB).
methodsWe conducted a retrospective cohort study of 1899 adult MPTB patients in the SEER database. Patients were categorized as having received RT (341) and not having received RT (1558). Baseline demographic data, tumor grade, AJCC stage, surgery approach, chemotherapy, and local lymphatic biopsy were extracted. Breast cancer-specific survival (BCSS) and overall survival (OS) of MPTB patients before and after propensity score matching (PSM) were compared using Kaplan-Meyer analysis. Predictors of RT were studied using multifactorial logistic regression. Multivariate Cox proportional risk regression was used to calculate hazard ratio (HR) and 95% confidence interval (CI) for outcome-related factors. Subgroup analyses explored effect modification by grade, stage, and surgery.
resultMultifactorial logistic regression showed that year of diagnosis, tumor grade, surgical approach and adjuvant chemotherapy were significant predictors of RT. Kaplan-Meier analysis showed that BCSS and OS were worse in the RT group before PSM (both p < 0.001), and there was no significant difference between the two groups after PSM (both p > 0.05). In a multifactorial Cox model, RT was not associated with BCSS (HR 0.975; 95% CI 0.699-1.36; p = 0.881) and OS (HR 0.867; 95% CI 0.662-1.135; p = 0.299) in MPTB patients. Classification of MPTB patients by tumor grade, AJCC.T, AJCC.N, and surgical approach did not identify subgroups that would benefit from long-term survival outcomes (BCSS or OS) from RT (all p > 0.05).
conclusionsIn this large retrospective cohort of MPTB patients, adjuvant RT was not associated with improved long-term survival-even among those with high-risk features. Prospective studies are needed to further clarify its therapeutic value.
Indexed as
Identifiers
41273477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.